[Adverse events in biologics for severe asthma].
Fiche publication
Date publication
avril 2024
Journal
Revue des maladies respiratoires
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BONNIAUD Philippe, Dr BELTRAMO Guillaume
Tous les auteurs :
Dargentolle G, Georges M, Beltramo G, Poisson C, Bonniaud P
Lien Pubmed
Résumé
Asthma is a pathology that remains severe and is inadequately controlled in 4% of patients. Identification of multiple pathophysiological mechanisms has led to the development of biomedicines, of which there are currently five available in France, with a safety profile that appears favorable but remains uncertain due to a lack of real-life experience with these new molecules.
Mots clés
Adverse events, Asthme sévère, Biologic, Biothérapies, Effets indésirables, Hypereosinophilia, Hyperéosinophilie, Pharmacovigilance, Severe asthma
Référence
Rev Mal Respir. 2024 04 22;: